Alessandro Padova appointed General Manager of Siena Biotech

30-Sep-2011 - The Board of Directors of Siena Biotech SpA has appointed Alessandro Padova as General Manager of the Company, reporting directly to the Board, while Dr. Giovanni Gaviraghi who covered both functions to present, will maintain his role of C.E.O. with strategic responsibilities. In this function ...

Aptuit and Siena Biotech Announce Strategic Relationship in Italy

30-Jul-2010 - Aptuit, Inc., and Siena Biotech S.p.A, announced a strategic partnership in which Siena Biotech will take a minority stake in Aptuit’s Italian operations in Verona, Italy, and Aptuit will become a provider of choice for Siena Biotech’s development pipeline. Under the agreement Aptuit and Siena ...

Exploring the Davids and Goliaths of therapeutic molecules

A*STAR inks deals with Siena Biotech to develop small- and large-molecule therapies for cancer and bone loss diseases

12-Apr-2010 - Two research units under Singapore’s Agency for Science, Technology and Research (A*STAR), the Experimental Therapeutics Centre (ETC) and Singapore Immunology Network (SIgN), are collaborating with Italy’s Siena Biotech S.p.A. to develop new drugs and targeted antibodies respectively, which will ...

Roche exercises option on compounds from collaboration with Siena Biotech

New molecules could offer innovative treatment approach for Alzheimer’s Disease

06-Apr-2010 - Siena Biotech S.p.A. announced that Roche will exercise its option early to become the lead party for further development, manufacture and commercialization of certain selected candidate molecules for a better treatment of Alzheimer’s Disease. Under the terms of the collaboration, Siena Biotech ...

Roche and Siena Biotech enter Research Collaboration Agreement in Neurodegenerative diseases

22-May-2007 - Siena Biotech S.p.A., announced that they have entered into a Research and Collaboration Agreement with Roche to perform joint research activities targeted towards treatment of selected neurodegenerative diseases. "This Collaboration Agreement with Roche is an excellent example of our commitment ...

Elixir Pharmaceuticals and Siena Biotech S.p.A. enter Agreement to Evaluate SIRT1 Inhibitors in Huntington's Disease

19-Feb-2007 - Elixir Pharmaceuticals, Inc. and Siena Biotech S.p.A. announced that the two companies have entered into an agreement to collaborate on the optimization, validation and evaluation of Elixir's SIRT1 inhibitors in Huntington's disease. SIRT1 is a member of the Sirtuin class of protein deacetylase ...

Wyeth and Sienabiotech announce R.& D. collaboration in the field of neurodegenerative diseases

Agreement to maximise research synergies for new molecules active against Alzheimer's Disease

07-Oct-2004 - Roma. Sienabiotech S.p.A., announced that they entered into an agreement with Wyeth Pharmaceuticals, a division of Wyeth to perform joint research and co-develop novel compounds, targeted towards treatment of neurodegenerative diseases and in particular Alzheimer's disease. Alzheimer's disease ...

ASINEX and SIENABIOTECH announce Lead Generation Collaboration

31-Mar-2004 - Siena and Moscow. ASINEX Ltd, a worldwide leader in lead generation and lead optimization, will perform computational work for SIENABIOTECH S.p.A., an integrated drug discovery company. ASINEX's computational department based on the information provided by SIENABIOTECH (undisclosed target & ...